KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Change in Acquisitions & Divestments: 2021-2023

Historic Change in Acquisitions & Divestments for Recursion Pharmaceuticals (RXRX) over the last 1 years, with Sep 2023 value amounting to $480,000.

  • Recursion Pharmaceuticals' Change in Acquisitions & Divestments fell 99.22% to $480,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $231.1 million, marking a year-over-year decrease of 22.92%. This contributed to the annual value of $480,000 for FY2023, which is 99.79% down from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Change in Acquisitions & Divestments of $480,000 as of Q3 2023, which was down 99.22% from $61.5 million recorded in Q3 2022.
  • Recursion Pharmaceuticals' Change in Acquisitions & Divestments' 5-year high stood at $147.6 million during Q1 2022, with a 5-year trough of $480,000 in Q3 2023.
  • Over the past 3 years, Recursion Pharmaceuticals' median Change in Acquisitions & Divestments value was $61.5 million (recorded in 2022), while the average stood at $60.1 million.
  • Data for Recursion Pharmaceuticals' Change in Acquisitions & Divestments shows a maximum YoY crashed of 99.22% (in 2023) over the last 5 years.
  • Quarterly analysis of 3 years shows Recursion Pharmaceuticals' Change in Acquisitions & Divestments stood at $69.2 million in 2021, then reached $61.5 million in 2022, then tumbled by 99.22% to $480,000 in 2023.
  • Its last three reported values are $480,000 in Q3 2023, $61.5 million for Q3 2022, and $21.4 million during Q2 2022.